Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Ocugen, inc. crawled time : 12:30 save search
Ocugen to Present at Investing in Cures Summit
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: -1.9%
H: 3.73%
C: 2.76%
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
Published: 2024-01-16 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: -0.6%
H: 0.52%
C: -5.87%
business
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
Published: 2023-12-19 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 4.81%
H: 2.03%
C: 0.97%
ocu400 treatment designation advanced therapy
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Published: 2023-12-13 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 2.22%
H: 0.54%
C: -0.03%
ocu410 first macular trial
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Published: 2023-11-29 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 0.53%
H: 3.95%
C: 1.71%
ceo conference growth
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
Published: 2023-11-10 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 0.0%
H: 1.49%
C: -2.33%
ocu410 disease trial
Ocugen, Inc. to Present at the 34th Annual ROTH Conference
Published: 2022-03-09 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 1.23%
H: 8.91%
C: 7.29%
conference
Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request
Published: 2022-03-04 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: -26.75%
H: 18.67%
C: 4.98%
xin authorization merge emergency use authorization
Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options
Published: 2022-02-15 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 3.16%
H: 3.86%
C: 3.86%
covid-19 america covid vaccine
New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
Published: 2021-12-15 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 5.61%
H: 9.84%
C: 6.69%
bbv152 covid-19 xin covid vaccine
Ocugen, Inc. Announces U.S. FDA Acceptance of Investigational New Drug Application to Initiate a Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
Published: 2021-12-09 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 7.46%
H: 0.31%
C: -12.81%
ocu400 new drug fda application gene therapy drug trial fda acceptance phase 1 therapy retina
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
Published: 2021-11-26 (Crawled : 12:30) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: -15.49%
H: 19.5%
C: 7.5%
bbv152 covid new drug fda application xin vaccine drug phase 3 trial clinical hold
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.